{"doi":"10.1002/ohn.182","title":"Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>To explore whether deintensification of adjuvant therapy reduces ototoxicity among patients with human papillomavirus (HPV)‐related oropharyngeal squamous cell carcinoma (OPSCC).</jats:p></jats:sec><jats:sec><jats:title>Study Design</jats:title><jats:p>Retrospective cohort study.</jats:p></jats:sec><jats:sec><jats:title>Setting</jats:title><jats:p>Single academic center.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The ototoxicity rate among adult patients with HPV‐related OPSCC enrolled in the Minimalist Trial (MINT), a prospective phase 2 trial of surgery followed by risk‐adjusted deintensified adjuvant therapy (42 Gy radiation given alone or with a single 100 mg/m<jats:sup>2</jats:sup> dose of cisplatin), was compared to that among a historical cohort treated with standard adjuvant therapy (60‐66 Gy radiation with up to three 100 mg/m<jats:sup>2</jats:sup> doses of cisplatin). Ototoxicity was defined as Common Terminology Criteria for Adverse Events v5.0 ≥ Grade 2. Mixed model analysis was performed to investigate the association between deintensified adjuvant therapy and treatment‐related hearing loss.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 29 patients (58 ears) were analyzed in the MINT cohort, and 27 patients (54 ears) in the historical cohort. The ototoxicity rate was 5% (n = 3/58 ears) in the MINT cohort and 46% (n = 25/54 ears) in the historical cohort (difference, 41%; 95% confidence interval [CI] = 27%‐56%). Patients in the MINT cohort demonstrated a 95% decrease in risk of ototoxicity compared to those in the historical cohort (adjusted odds ratio: 0.05, 95% CI = 0.01‐0.31). Differences in estimated marginal mean threshold shifts were statistically and clinically significant at frequencies ≥ 3 kHz.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>The deintensified adjuvant therapy given in MINT led to less ototoxicity than standard adjuvant therapy among patients with HPV‐related OPSCC.</jats:p></jats:sec>","journal":"Otolaryngology–Head and Neck Surgery","year":2023,"id":641051,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1666428,"name":"Rajwant S. Mahal","orcid":null,"position":1,"is_corresponding":false},{"id":918536,"name":"Theresa Tharakan","orcid":"0000-0002-2399-2343","position":2,"is_corresponding":false},{"id":1092946,"name":"Cathryn Collopy","orcid":null,"position":3,"is_corresponding":false},{"id":231284,"name":"Dorina Kallogjeri","orcid":"0000-0001-5365-0988","position":4,"is_corresponding":false},{"id":231281,"name":"Wade L. Thorstad","orcid":"0000-0002-2757-0543","position":5,"is_corresponding":false},{"id":231289,"name":"Douglas R. Adkins","orcid":"0000-0003-3207-8227","position":6,"is_corresponding":false},{"id":231267,"name":"Peter Oppelt","orcid":"0000-0001-6685-1762","position":7,"is_corresponding":false},{"id":231266,"name":"Jessica Ley","orcid":"0000-0001-5092-8884","position":8,"is_corresponding":false},{"id":862275,"name":"Cameron C. Wick","orcid":"0000-0003-1779-2385","position":9,"is_corresponding":false},{"id":1666429,"name":"Jose Zevallos","orcid":null,"position":10,"is_corresponding":false},{"id":453087,"name":"David S. Lee","orcid":"0000-0001-7286-325X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>To explore whether deintensification of adjuvant therapy reduces ototoxicity among patients with human papillomavirus (HPV)‐related oropharyngeal squamous cell carcinoma (OPSCC).</jats:p></jats:sec><jats:sec><jats:title>Study Design</jats:title><jats:p>Retrospective cohort study.</jats:p></jats:sec><jats:sec><jats:title>Setting</jats:title><jats:p>Single academic center.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The ototoxicity rate among adult patients with HPV‐related OPSCC enrolled in the Minimalist Trial (MINT), a prospective phase 2 trial of surgery followed by risk‐adjusted deintensified adjuvant therapy (42 Gy radiation given alone or with a single 100 mg/m<jats:sup>2</jats:sup> dose of cisplatin), was compared to that among a historical cohort treated with standard adjuvant therapy (60‐66 Gy radiation with up to three 100 mg/m<jats:sup>2</jats:sup> doses of cisplatin). Ototoxicity was defined as Common Terminology Criteria for Adverse Events v5.0 ≥ Grade 2. Mixed model analysis was performed to investigate the association between deintensified adjuvant therapy and treatment‐related hearing loss.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 29 patients (58 ears) were analyzed in the MINT cohort, and 27 patients (54 ears) in the historical cohort. The ototoxicity rate was 5% (n = 3/58 ears) in the MINT cohort and 46% (n = 25/54 ears) in the historical cohort (difference, 41%; 95% confidence interval [CI] = 27%‐56%). Patients in the MINT cohort demonstrated a 95% decrease in risk of ototoxicity compared to those in the historical cohort (adjusted odds ratio: 0.05, 95% CI = 0.01‐0.31). Differences in estimated marginal mean threshold shifts were statistically and clinically significant at frequencies ≥ 3 kHz.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>The deintensified adjuvant therapy given in MINT led to less ototoxicity than standard adjuvant therapy among patients with HPV‐related OPSCC.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36939390","pmcid":null,"openalex_id":"https://openalex.org/W4317506875","authors":[],"funders":[{"funder_name":"NIDCD NIH HHS","grant_id":"T32 DC000022","title":null}],"total_grants":1,"fwci":0.8067,"citation_percentile":0.64794976,"influential_citations":0,"citation_trend":[{"year":2024,"count":1},{"year":2025,"count":3},{"year":2026,"count":1}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ohn.182","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ohn.182","host_type":"publisher"},{"url":"https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/ohn.182","host_type":"publisher"},{"url":"https://doi.org/10.1002/ohn.182","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36939390","host_type":"repository"}],"fields_of_study":["Hearing, Cochlea, Tinnitus, Genetics","Hearing Loss and Rehabilitation","Vestibular and auditory disorders","Adult","Humans","Squamous Cell Carcinoma of Head and Neck","Carcinoma, Squamous Cell","Human Papillomavirus Viruses","Oropharyngeal Neoplasms","Cisplatin","Retrospective Studies","Papillomavirus Infections","Prospective Studies","Ototoxicity","Head and Neck Neoplasms","Hearing"],"mesh_terms":["Squamous Cell Carcinoma of Head and Neck","Ototoxicity","Human Papillomavirus Viruses","Adult","Carcinoma, Squamous Cell","Cisplatin","Head and Neck Neoplasms","Hearing","Humans","Oropharyngeal Neoplasms","Prospective Studies","Retrospective Studies","Papillomavirus Infections"],"keywords":["Medicine","Oncology","Basal cell","Adjuvant","Internal medicine","Adjuvant therapy","Cancer","P16+","Cisplatin Ototoxicity","Hearing Outcomes","Hpv-related Oropharyngeal Squamous Cell Carcinoma","Treatment Deintensification"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T15:38:22.355223Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}